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Abstract
Osteocytes regulate bone turnover and mineralization in chronic kidney disease (CKD). Since 
osteocytes are derived from osteoblasts, alterations in osteoblast function may regulate osteoblast 
maturation, osteocytic transition, bone turnover and skeletal mineralization. Thus, primary 
osteoblasts-like cells were cultured from bone chips obtained from 24 pediatric ESKD patients. 
RNA expression in cultured cells was compared to RNA expression in cells from healthy 
individuals, to RNA expression in the bone core itself, and to parameters of bone 
histomorphometry. Proliferation and mineralization rates of patient cells were compared to rates in 
healthy control cells. Associations were observed between bone osteoid accumulation, as assessed 
by bone histomorphometry, and bone core RNA expression of osterix, matrix gla protein, PTH 
receptor 1, and RANKL. Gene expression of osteoblast markers was increased in cells from 
ESKD patients and signaling genes including Cyp24A1, Cyp27B1, VDR, and NHERF1 correlated 
between cells and bone cores. Cells from patients with high turnover renal osteodystrophy 
proliferated more rapidly and mineralized more slowly than did cells from healthy controls. Thus, 
primary osteoblasts obtained from patients with ESKD retain changes in gene expression ex vivo 
that are also observed in bone cores specimens. Evaluation of these cells in vitro may provide 
further insights into the abnormal bone biology that persists, despite current therapies, in patients 
with ESKD.
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INTRODUCTION
Recent discoveries in the field of chronic kidney disease mineral and bone disorder (CKD-
MBD) have led to a major shift in the way that bone metabolism and bone cell biology are 
viewed in the context of systemic disease (1–5). Indeed, osteocytes, the predominant cell 
type in mineralized bone, were long thought to be relatively quiescent cells, with a function 
limited to transduction of signals related to mechanical stress (6). These cells, which are 
derived from osteoblasts, are now known to secrete hormones which regulate mineral 
metabolism and control skeletal mineralization. CKD is associated with altered osteocytic 
protein expression (7) and abnormally elevated circulating levels of at least one osteocytic 
hormone—fibroblast growth factor 23 (FGF23)—have been linked to systemic disease, 
including cardiovascular disease(8), in CKD.
Much current interest is focused on the role of osteocytes in the control of CKD-MBD; 
however, the study of these human cells, both in healthy individuals and in the context of 
kidney disease, is limited by the fact that osteocytes are terminally differentiated cells that 
exist in a mineralized milieu, limiting their potential to be isolated and propagated in cell 
culture. However, osteocytes are differentiated from osteoblasts and primary human 
osteoblast-like cells have been isolated from humans with CKD and other bone disorders 
and have been evaluated in culture since the 1980s (9, 10). These cells may be induced to 
transition to an osteocytic phenotype in culture under mineralizing conditions (9, 10), thus 
allowing for the study of osteoblast maturation and osteocyte transition in both healthy 
individuals and in patients with CKD. Previous in vivo and in vitro studies have 
demonstrated that both circulating factors and those intrinsic to osteoblasts themselves 
contribute to differences in osteoblast characteristics between patients with different types of 
renal osteodystophy; ideed, primary osteoblasts obtained from patients with end-stage 
kidney disease have been shown to exhibit differences in proliferative characteristics ex vivo 
(11, 12) (13). However, the mechanisms underlying the changes in bone cell phenotype 
observed in CKD patients remain poorly understood. Therefore, we created and 
characterized a model system that may be used to study this abnormal phenotype, 
performing analysis of gene expression in whole bone biopsy samples and in cultures of 
osteoblast precursors derived from the same patients.
RESULTS
Study subjects
Twenty-four pediatric patients (14M, 10F) with end-stage kidney disease (ESKD) treated 
with maintenance dialysis were included in the study. Subjects were 17.1 ± 0.7 years of age, 
were primarily Hispanic (83%), and had varying types of renal osteodystrophy (Figure 1). 
Eight subjects were treated with active vitamin D sterols (doxercalciferol or calcitriol) at the 
time of biopsy; 16 subjects were not on active vitamin D sterols for at least 4 weeks prior to 
the biopsy. Biochemical parameters of the subjects at the time of the biopsy are displayed in 
Table 1 and bone histologic variables are displayed in Table 2.
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Bone core RNA, biochemical values, and bone histology
Consistent with the heterogeneous cellular composition of bone, both osteoblastic and 
osteocytic marker gene expression were readily detectable in bone cores from patients with 
ESKD, and, for the most part, the expression of these markers was increased compared to 
the healthy controls. These data suggest that the gene expression reflects abnormalities in 
osteoblast function that can be observed histologically. Differences in expression of 
osteoblast and osteocyte marker genes were not evident between patients with different 
types of bone histology (adynamic or normal bone turnover versus high bone turnover) or 
based on the presence or absence of active vitamin D sterol treatment and the tight range of 
ages precluded any assessment of the effect of age on gene expression. Therefore, data from 
the different patient groups were pooled for subsequent analysis.
When examining genes involved in vitamin D metabolism, expression of Cyp27B1 and 
VDR were found to be increased in cores from patients with ESKD with respect to controls, 
whereas expression of Cyp24A1 was decreased. Expression of FGFR1, the receptor for the 
classical actions of FGF23, was increased in patient biopsies compared with controls as 
were genes critical to PTH signaling, including the PTH receptor (PTHR1) and Na+/H+ 
Exchange Regulatory Co-Factor (NHERF1), a scaffold protein that interacts with the PTHR. 
Moreover, expression of osteocyte marker genes was significantly increased in patient 
samples (Table 3).
Consistent with the previously observed correlation between plasma concentrations of 
FGF23, bone protein FGF23, and bone mineralization (14), bone core FGF23 RNA was 
inversely related to circulating alkaline phosphatase values (r= − 0.53, p=0.01), osteoid 
thickness (O.Th) (r= − 0.55, p=0.01, Figure 2), osteoid volume (OV/BV) (r= − 0.53, 
p=0.01), and mineralization lag time (MLT) (r= − 0.47, p=0.04). Osteocyte marker gene 
expression was markedly increased in bone cores of patients as compared to control bone. 
Measurements of osteoblast surface (Ob.S/BS) also correlated directly with multiple 
osteoblastic markers (osterix: r=0.53, p=0.01; matrix gla protein r=0.46, p=0.03; and type 1 
collagen: r=0.55, p=0.01) as well as with signaling markers (PTH receptor 1 (PTHR1): 
r=0.51, p=0.02 and receptor activator of nuclear factor kappa-B ligand (RANKL): r=0.46, 
p=0.03). Vitamin D sterol therapy did not modify the correlations between bone core RNA 
and bone histomorphometry. No correlations were observed between bone formation rate 
and osteoblastic or osteocytic marker gene expression, either before or after normalizing 
bone core gene expression by osteoblast surface.
Bone cell RNA, biochemical values, and bone histology
To determine whether primary cultures of ESKD patient-derived osteoblastic cells could 
serve as a model system for studying changes in variations in osteoblast and osteocyte 
biology associated with this disease, RNA was isolated from osteoblastic cells derived from 
bone biopsy samples and gene expression of osteoblast and osteocyte markers was assessed 
relative to expression in normal control cells. For the most part, expression of osteoblast 
marker genes was up-regulated in confluent cultures of primary osteoblasts obtained from 
patients as compared to healthy control cells (Figure 3). However, expression of osteocalcin 
(bone gamma-carboxyglutamic acid-containing protein, BGLAP) was not increased in these 
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confluent cultures, demonstrating their early stage of osteoblastic differentiation (Figure 4). 
Interestingly, whereas expression of Cyp24a1 was decreased compared to controls in the 
bone cores, expression of this gene tended to increase in the cultured cells. Conversely, 
expression of Cyp27B1, which was increased in bone cores, was unchanged in the isolated 
cells. Consistent with the source of cells—i.e. of an osteoblast phenotype—PTHR1 
expression from primary osteoblasts correlated with osteoblast surface on bone 
histomorphometry (r= −0.53, p<0.01). As expected, osteocytic gene expression was low in 
confluent cultures from both healthy controls and from ESKD patients and no correlations 
were observed between expression of these genes and parameters of bone 
histomorphometry. Unlike the bone cores, correlations between cell RNA and circulating 
biochemical values were not observed. Neither therapy with active vitamin D sterols nor 
subject age altered the relationship between cellular gene expression and bone 
histomorphometry.
In vitro osteoblast differentiation, mineralization, and proliferation
To confirm that the confluent cultures of osteoblastic cells possessed the ability to grow, 
differentiate and deposit mineralized matrix and to assess whether changes in gene 
expression observed in cells from ESKD patients were related to an altered phenotype, 
proliferation and mineralization assays were performed using osteoprogenitors from 3 
healthy controls and from 3 patients. Patient cells were chosen from one representative 
subgroup of renal bone disease, namely high turnover renal osteodystrophy. The time from 
when the biopsies were performed until the cells had reached confluence was affected by the 
number and size of the bone chips obtained from each biopsy specimen; thus, progeny of the 
cells were plated at equal density and proliferation and mineralization characteristics 
evaluated in these progeny. The results demonstrated that the number of proliferating cells 
from healthy controls increased 35.6 ± 8.5% while cells from ESKD patients with high bone 
turnover plated at the same density grew by 91.1 ± 14.1% (p<0.05 from controls) by 72 
hours (Figure 5). Cells from healthy controls maintained in an osteoblast differentiation 
cocktail containing ascorbic acid, β-glycerolphosphate, and dexamethasone began to 
mineralize by week 2 in culture while mineralization was delayed in cells from the ESKD 
patients (Figure 6). Immunocytochemistry for osteocalcin was positive in mineralizing cells, 
further confirming that the cultured cells were of an osteoblast lineage (Figure 5).
Bone core RNA and bone cell RNA
Correlations between gene expression in cores and cells are displayed in Table 3. Most 
notably, genes involved in vitamin D signaling correlated well between RNA obtained from 
bone itself and RNA obtained from cultured primary osteoblasts (Cyp24A1: r=0.42, p=0.05; 
Cyp27B1: r=0.73, p=0.0001; and VDR: r=0.45, p=0.04). Similarly, selected elements of 
PTH signaling (NHERF1: r=0.64, p=0.001) and growth hormone signaling pathways (IGF1: 
r=0.47, p=0.03) correlated between whole bone and cultured primary osteoblast RNA. As 
expected, genes specific to an osteocytic phenotype did not correlate between whole bone 
cores, whose cellular make-up consists of a high percentage of osteocytes, and cultured 
primary osteoblasts, reflecting the early differentiation status of the confluent cultures. In 
this small sample, ongoing in vivo therapy with active vitamin D sterols at the time of bone 
Pereira et al. Page 4
Kidney Int. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
biopsy did not affect the relationship between bone core and primary osteoblast cell RNA 
expression.
DISCUSSION
The current study demonstrates that primary human osteoblast-like cells can be cultured 
from bone fragments obtained from pediatric ESKD and healthy control subjects at the time 
of bone biopsy. These cells express osteocalcin and can be induced to mineralize, thus 
confirming an osteoblastic phenotype. Cells from these adolescent patients with ESKD have 
increased expression of genes crucial to the mineralization process and these changes in 
gene expression persist in culture as the cells divide and grow to confluence. Expression of 
osteoblastic genes in vitro correlate with osteoblastic gene expression from bone cores 
themselves and this expression is related to histomorphometric indices.
Currently, much interest and research are focused on the role of different osteocytic proteins 
in CKD and its complications. We have previously demonstrated that osteocytes in pediatric 
patients with all stages of CKD express excessive amounts of FGF23, a protein which 
appears to play in important role in the development of secondary hyperparathyroidism (7). 
These individuals display defects in skeletal mineralization, even in very early CKD when 
circulating concentrations of calcium, phosphorus, PTH and 1,25(OH)2vitamin D are within 
the normal range (14), suggesting that altered bone cell biology may contribute to these 
abnormalities. The current results demonstrate that abnormalities in RNA expression persist 
in primary human osteoblast-like cells from pediatric ESKD patients removed from the 
uremic milieu, as do abnormalities in proliferation and mineralization characteristics. Since 
abnormal expression of osteocytic proteins such as FGF23 has been linked to systemic 
consequences, such as cardiovascular disease, progressive renal dysfunction, and mortality 
in patients with CKD (8, 15), and since osteocytes are derived from osteoblasts, further 
characterization of the maturation and mineralization characteristics of these primary 
osteoblast-like cells may yield valuable insights into the pathogenesis of both bone and 
cardiovascular disease in CKD.
Previous in vivo and in vitro data have demonstrated that circulating factors contribute to 
differences in osteoblast proliferation; indeed, IGF1 and PTH both stimulate bone formation 
rates while circulating inhibitors of osteoblast mitogenesis have also been identified in 
uremic serum (16). It has also been suggested that factors intrinsic to osteoblasts themselves 
may contribute to differences in osteoblast characteristics between patients (11–13). The 
current study expands these findings, demonstrating that cellular gene expression of both 
early and later osteoblast markers from primary human osteoblast-like cells are increased in 
cells obtained from adolescent dialysis patients when compared to control cells from healthy 
adolescents. Osteocytic gene expression, however, appears to be very low in these cell 
cultures, demonstrating that the predominant cell type in ossified bone—namely osteocytes
—do not migrate and/or survive in these cell culture conditions. However, osteocytes are 
derived from mature osteoblasts and since abnormal expression of osteocytic proteins such 
as FGF23 have been linked to systemic consequences such as cardiovascular disease, 
progressive renal dysfunction, and mortality in patients with CKD (8, 15, 17), the ability to 
use these primary osteoblast-like cells, which are able to mineralize, to study potential 
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abnormalities in osteoblast to osteocyte transition may greatly improve understanding of the 
origins of not only bone, but also cardiovascular disease in CKD.
Although some osteoblastic markers in cells from adolescent CKD patients appear 
upregulated—including factors required for osteoblast maturation—expression of signaling 
genes were not increased. Induction—such as by vitamin D sterol therapy—might change 
gene expression in bone cores that is not carried over into subsequent generations of primary 
osteoblasts and circulating factors—including 1,25(OH)2vitamin D, 25(OH)vitamin D, and 
IGF-1—may similarly affect the bone cores in a way that is not reflected in primary 
osteoblasts and their progeny once removed from the uremic milieu. This may explain why 
many genes evaluated in the current study did not correlate directly between cells and bone 
cores. However, it is interesting to note that expression of factors involved in vitamin D 
(Cyp24 and Cyp27), PTH (PTHR1), and FGF23 (FGFR1) signaling did correlate directly 
between cells and their respective bone cores, suggesting that expression of these genes 
were not primarily influenced by circulating factors in the uremic milieu.
In the current study, expression of osteocytic genes, as well as of osteoblastic genes, was 
markedly upregulated in bone core tissue itself—an expected finding given that osteocytes 
comprise the majority of cells in bone. The increased amount of PTHR1 mRNA found in 
bone cores of dialysis patients appears to differ from previous data by Picton and colleagues 
(18) in which in situ hybridization noted a decrease in PTHR1 mRNA overlying osteoblasts 
in bone from patients with ESKD. However, the current data reflect RNA from whole bone, 
including bone marrow and osteocytes, in addition to the osteoblasts evaluated by Picton et 
al. Since PTHR1 is expressed on osteocytes, the most abundant cell-type in mineralized 
bone, the current findings may reflect increased expression of the PTH receptor on these 
cells specifically (19). The inverse correlations between bone core FGF23 RNA and osteoid 
accumulation are consistent with previous reports documenting the same relationship 
between osteocytic FGF23 protein expression, circulating FGF23 levels and osteoid 
accumulation in dialysis patients (3, 20). The reason behind this inverse relationship is not 
clear and warrants further investigation since it is not possible to tell from cross-sectional 
studies whether this represents a positive effect of FGF23 expression on skeletal 
mineralization or whether FGF23 expression is a reflection of the quality of mineral content 
in the surrounding bone, as suggested by recent studies by David et al (21). The mechanism 
by which FGF23 mRNA is increased in bone in CKD remains poorly understood. However, 
Martin et al suggest that stimulation of FGF23 may occur via FGFR1 (22), findings which 
are consistent with the current data in which FGF23 and FGFR1 expression are 
simultaneously increased in CKD bone.
Since the primary cells obtained from the current method were polyclonal, their RNA 
expression reflects that of osteoblasts from multiple precursors. This observation is 
important as osteocytes, the mature form of osteoblasts, have been found to be a 
heterogeneous cell type in patients with CKD, with osteocytes in different areas of both 
trabecular and cortical bone expressing different quantities of proteins such as FGF23 and 
DMP1 (20). Whether differences in osteocytic phenotype is related to cell maturity or is 
related to more fundamental differences in cell origin or environment is unknown, but 
warrants further investigation.
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In summary, primary osteoblast-like cells obtained from patients with ESKD retain changes 
in gene expression, as well as in proliferation and mineralization characteristics, ex-vivo. 
These cells provide a novel in vitro model by which critical aspects of CKD-MBD, 
including changes in osteoblast proliferation and maturation and the effects of different 
circulating hormones on cells of this lineage, may be evaluated. In addition to advancing 
current understanding as to the pathogenesis of renal osteodystrophy, this model may also 
provide insights into the pathogenesis of systemic complications, including progressive renal 
dysfunction and cardiovascular disease, both of which have been linked to increased bone 
protein expression in the context of CKD.
METHODS
Patients
Sequential pediatric patients with ESKD who were treated with chronic cycling peritoneal 
dialysis (CCPD) and who underwent trans-iliac bone biopsy at UCLA between January 
2008 and March 2011 were included in the study (Figure 7). Patients with metabolic bone 
disease other than renal osteodystrophy, those who had undergone parathyroidectomy within 
the preceding year, and those who had been treated with immunosuppressive therapy or 
recombinant human growth hormone within the previous year were excluded from study 
participation. All subjects underwent double tetracycline labeling prior to the bone biopsy. 
At the time of the bone biopsy, 2 bone cores were obtained. The first core, measuring 5 mm 
in diameter, was placed in 70% ethanol and then prepared, sectioned, and evaluated for bone 
histomorphometric parameters. The second core, which measured 2 mm in diameter, was 
collected in Dulbecco’s Modified Eagle’s Medium (DMEM). In the laboratory, this second 
core was divided into two equal pieces. The first piece was placed directly in TRIzol 
(Invitrogen, Carlsband, CA, USA) and frozen at −80°C. Muscle and cortical bone were 
removed from the second piece which was then minced and placed in culture (see below). 
Biochemical determinations of blood concentrations of calcium, phosphorus, PTH, alkaline 
phosphatase, 25(OH)vitamin D, and FGF23 were obtained at the time of bone biopsy. 
Serum calcium, phosphorus, albumin, creatinine, and alkaline phosphatase values were 
assessed using an Olympus AU5400 analyzer (Olympus America Incorporated, Center 
Valley, PA). PTH concentrations in EDTA plasma were measured by the 1st generation 
immunometric assay (ImmutopicsR, San Clemente, California, normal range: 10–65 pg/ml). 
FGF23 levels were determined in EDTA plasma by a 2nd generation C-terminal assay 
(ImmutopicsR, San Clemente, California). The normal range (<100 RU/mL) was defined by 
Isakova et al. (23) and confirmed in a cohort of 42 healthy children age 12 ± 4 years (24). 
25(OH)vitamin D and 1,25(OH)2vitamin D levels were measured by radioimmunoassay 
(25).
Control samples for the PCR data were obtained from 4 subjects, ages 14, 15, 16 and 38 
years, undergoing surgery for idiopathic scoliosis or for maxillofacial surgery requiring 
grafting. All control subjects were of normal statural height with normal body mass index 
(height Z score SDS: −0.1 (−0.3, 0.8); weight Z score SDS: 0.7 (0.2, 1.1)), normal kidney 
function, and normal acid/base parameters. All samples were of trabecular bone obtained 
from either the hip or spine. All of the control fragments were obtained in the operating 
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room and were immediately placed in preservative solutions by the operating surgeons. In 
the laboratory, the cortical bone was carefully removed from all control samples, similar to 
its removal from patient samples. Two of the controls were Hispanic and 3 were female. 
Due to their similarities in age to the study population, the three controls aged 14 to 16 years 
were selected for the proliferation and mineralization studies. The study was approved by 
the UCLA Institutional Review Board and consent/assent was obtained from all patients and 
their parents.
Isolation of RNA from bone cores
Total RNA was extracted from bone cores using TRIzol according to the manufacturer’s 
instructions. The pellet was then resuspended in RNase free water and measurement of RNA 
yield was performed using a NanoDrop 1000A Spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA). Reverse transcription reaction was performed for cDNA 
synthesis using High Capacity cDNA RT kit (Applied Biosystems, Foster City, CA 94404) 
according to the manufacturer’s instructions. Samples were then stored at −80°C. 
Quantitative real-time PCR (qPCR) amplification was performed using QuaniTect® Probe 
PCR kit (QIAGEN Inc, Helden Germany). Taqman assays were used to quantify expression 
of genes listed in Table 4. Sequence-specific probes are listed in Table 4. The housekeeping 
gene GAPDH was analyzed in every sample and used as an endogenous control for data 
normalization. Samples were assayed in triplicate. Relative quantification studies of 
threshold cycle (Ct) were performed with Sequence Detector software (Applied Biosystems, 
Foster City, CA). Relative gene expression in patient samples was expressed relative to the 
healthy controls.
Isolation and propagation of human osteoblast-like cells
Trabecular bone fragments were obtained from the second bone biopsy core, as described 
above, and were prepared according to the procedure adapted from Dillon et al (26). Briefly, 
bone fragments were washed with fresh media containing antibiotic and antimycotic (Anti-
Anti) (Gibco, Carlsbad, CA) upon arrival in the laboratory. The fragments were minced into 
very small pieces, divided into 6 tissue culture plates, and allowed to adhere for 2 hours in 
5% CO2 at 37°C (Figure 7). DMEM supplemented with 20% FBS and ascorbic acid (100 
ug/ml) was then added and the plates were incubated at 37°C. Once outgrowth of cells and 
their attachment to the plates were observed, the media was changed twice weekly until the 
formation of 10–20 cell colonies per plate was observed (1 to 4 weeks). The colonies of cell 
were trypsinized, pooled, and subcultured. When cells reached ~80% confluence, the 
contents of 19 plates were frozen in 20 ml of freezing media containing 10% DMSO and 
30% FBS and placed in liquid nitrogen for future use. The remaining plate was allowed to 
grow to confluence prior to RNA extraction, as described above.
Mineralization matrix formation
In order to confirm the osteoblastic potential of the cells isolated from bone chips, an aliquot 
of frozen cells from the 3 controls and 3 patients with high turnover renal osteodystrophy 
were thawed and seeded into 12 well plates at a density of 1 × 104 cells per well. Cells were 
cultured in DMEM with 10% FBS. At confluence the media was changed to an osteoblast 
differentiation cocktail containing 10−8 M dexamethasone, 10 mM β-glycerol phosphate, 
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and 100 µg/ml ascorbic acid for 1–4 weeks. The media was replaced twice weekly and the 
presence of mineralized nodules was assessed at weekly intervals using a 1% (w/v) solution 
of Alizarin Red S (pH 6.4) (Sigma-Aldrich, St. Louis MO); staining was quantified by 
extracting the dye from the cell layer using 10% acetic acid at 85°C for 30 minutes; the 
supernatant was analyzed at 405 nm. Cell number was estimated by staining parallel wells 
with 0.05% Crystal Violet; staining was quantified by extracting the dye from the cell layer 
by incubation in methanol for 30 min. The supernatant was analyzed at 570 nm. The 
quantity of Alizarin Red S was then normalized to that of Crystal Violet.
Immunocytochemistry
Cells were cultured on 8 chamber slides at a density of 1 × 104 cells per well. After 21 days 
of culture in osteoblast differentiation cocktail, cells were fixed with a 95% ethanol and 5% 
acetic acid for 10 minutes at −20°C. After washing with PBS, cells were permeabilized with 
0.1% (v/v) Triton X-100 (Sigma) for 45 minutes and washed again with PBS. Nonspecific 
binding was blocked by incubating in 1:20 horse serum (Sigma) for 1 hour. Cells were then 
incubated with mouse anti-human osteocalcin (R&D Systems, Minneapolis MN) at 4°C 
overnight. After washing with PBS, cells were incubated with secondary antibody (donkey 
Alexa-Fluor-488) (Invitrogen, Carlsbad CA) for 1 hour at room temperature. Nuclear 
counterstaining was performed with mounting medium containing DAPI (Vector, 
Burlingame CA).
Proliferation
Proliferation was assessed by tetrazolium incorportation [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H–tetrazolium, MTS] assay, using the 
CellTiter96® AQueous One Cell Proliferation Assay (Promega, Fitchburg, WI) according to 
manufacturer’s instructions. In brief, a frozen aliquot of primary osteoblast-like cells from 3 
healthy control subjects and 3 patients with high turnover renal osteodystrophy were thawed, 
grown to subconfluence and passaged 3 times. Cells were plated at 8,000 cells per well in 96 
well plates. Viable cells were quantified by the addition of 20µl of CellTiter96® AQueous 
One Solution Reagent per well and analyzed by spectrophotometry at 490 nm.
Bone histomorphometry
Five mm diameter specimens of iliac crest were dehydrated in alcohol, cleared with xylene, 
and embedded in methylmethacrylate. Static histomorphometric parameters were evaluated 
in undecalcified 5 µm sections treated with Toluidine blue stain; tetracycline labeling was 
assessed in unstained 10 µm sections. Primary bone histomorphometric parameters were 
assessed in trabecular bone under 200× magnification using the OsteoMetricsR system 
(OsteoMetrics, Decatur, GA) by a histomorphometrist (RP). Mineralized bone was defined 
by dark blue staining areas; pale-blue seams at least 1.5 µm in width were included in 
measurements of osteoid. Derived indices were calculated as described by Parfitt et al (27). 
Normal parameters of bone histomorphometry were defined from bone biopsies obtained 
from a previously described control group of 31 pediatric patients with normal kidney 
function (mean age 12.4 ± 1.5 years, 71% male, 48% Caucasian and 26% Hispanic) who 
were undergoing elective orthopedic surgery (28).
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Statistical analysis
Variables are reported as mean ± standard error or median (interquartile range). Skewed 
values were log-transformed prior to statistical analysis. Spearman correlation coefficients 
were used to express the relationship between bone histomorphometry and RNA expression 
for bone cores and cells. In select cases where distribution of both variables (or transformed 
values of those variables) was normal, Pearson correlation coefficients were also performed 
and the relationship between variables was displayed in a scatter plot. The Wilcoxon Signed 
Rank test was used to evaluate differences from healthy controls. Differences in 
proliferation rates between cells from healthy controls and CKD patients were assessed 
using a mixed model. All statistical analyses were performed using SAS software (SAS 
Institute Inc., Cary, NC) and all tests were two-sided. A probability of type I error less than 
5% was considered statistically significant and ordinary p values are reported.
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Figure 1. 
Lesions of renal osteodystophy on bone biopsy represented in the cohort of ESKD patients 
evaluated for osteoblast-like cell and bone core RNA. Adynamic bone (low bone turnover) 
(grey): n=6; normal bone turnover (striped): n=3; normal bone turnover with fibrosis 
(white): n=9; osteitis fibrosa (high bone turnover) (black): n=5; mixed uremic 
osteodystrophy (high bone turnover with defective mineralization) (checkered): n=1.
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Figure 2. 
Relationship between FGF23 RNA expression in bone cores and osteoid thickness (O.Th), 
as determined by bone histomorphometry.
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Figure 3. 
Gene expression of osteoblast markers in primary osteoblasts from ESKD patients. Values 
are expressed as a multiple of (fold of) the expression found in healthy control cells. Box 
plots indicate the medians (interquartile ranges); the 5th and 95th percentiles are denoted by 
the lower and upper whiskers, respectively. The asterisks denote significant (p<0.001) 
differences from healthy controls.
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Figure 4. 
Gene expression of cell signaling genes in primary osteoblasts from CKD patients. Values 
are expressed as a multiple of (fold of) the expression found in normal control cells. Box 
plots indicate the medians (interquartile ranges); the 5th and 95th percentiles are denoted by 
the lower and upper whiskers, respectively. The asterisks denote significant (p<0.001) 
differences from healthy controls.
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Figure 5. 
Mineralization rates in cells from dialysis patients with high turnover renal osteodystrophy 
as compared to those from healthy controls. A) Alizarin Red S staining of primary human 
osteoblast-like cells from healthy controls and dialysis patients with high turnover renal 
osteodystrophy grown under mineralizing conditions (10 mM β-glycerolphosphate and 100 
µg/ml ascorbic acid) for 7, 14, 21 and 28 days. B) Alizarin red stained mineralized nodules 
under light microscopy (40x) at 14, 21, and 28 days. C) Mineralization of primary 
osteoblast-like cells, as quantified by the ratio of absorbance of Alizarin Red S to Crystal 
violet (i.e. ratio of mineral content to cells), occurs more rapidly in cells from healthy 
controls (black bars) than in dialysis patients with high turnover renal osteodystrophy (open 
bars). The asterisk denotes significant (p<0.01) difference in Alizarin Red S to Crystal 
Violet absorbance ratios between dialysis patients with high turnover renal osteodystrophy 
and healthy controls. D) Primary osteoblast-like cells from healthy controls after 28 days in 
mineralizing conditions a) display mineralized nodules under light microscopy and b) 
express osteocalcin (green color) as detected by immunofluorescence. DAPI staining (c) 
confirms that osteocalcin expression localizes to living cells at the site of the mineralized 
nodule formation.
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Figure 6. 
Proliferation of primary human osteoblast-like cells as assessed by MTS incorporation. Data 
are expressed as percentage increase in absorbance from baseline. A higher proliferation rate 
was observed in dialysis patients with high turnover renal osteodystrophy (open symbols) 
than in controls (closed symbols) (p<0.01). The asterisk denotes a significant (p<0.01) 
difference in proliferation rates between groups.
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Figure 7. 
Flowchart of the study.
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Table 1
Biochemical and growth parameters from 24 dialysis patients at the time of bone biopsy
Parameter Patients
Calcium (mg/dl) 8.9 ± 0.2
Phosphorus (mg/dl) 6.5 ± 0.4
25(OH)vitamin D (ng/ml) 20.4 ± 2.0
Alkaline phosphatase (IU/l)* 160 (95, 283)
PTH (pg/ml) * 555 (357, 764)
FGF23 (RU/ml) * 1826 (425, 4825)
Height Z score (SDS) * −1.9 (−2.7, −0.2)
Weight Z score (SDS) * −0.6 (−1.8, 0.8)
*
Indicates that the value is displayed as the median (interquartile range) due to non-normal distribution. All other values are displayed as mean ± 
SEM.
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Table 2
Bone histomorphometry in 24 dialysis patients undergoing bone biopsy.
Value Normal range
Turnover
Bone formation rate (BFR/BS) (µm3/um2/y) * 25.6 (8.0, 63.9) 8.0–73.4
Eroded surface (ES/BS) (%) 9.1 ± 1.0 0.5–4.3
Mineralization
Osteoid volume (OV/BV) (%) 4.5 ± 0.7 0.2–5.8
Osteoid thickness (O.Th) (µm) 8.9 ± 0.6 2.0–13.2
Osteoid surface (OS/BS) (%) 31.0 ± 3.2 4.3–37.0
Osteoid maturation time (OMT) (d) 12.1 (8.9, 14.9) 1.2–11.5
Mineralization lag time (MLT) (d) * 32.8 (20.4, 56.2) 2.3–63.8
Volume
Bone volume (BV/TV) (%) 32.0 ± 1.9 8.9–34.4
Trabecular number (Tb.N) (#/mm2) 2.1 ± 0.1 1.1–2.2
Trabecular separation (Tb.Sp) (µm) 347 ± 34 351–737
*
Indicates that the value is displayed as the median (interquartile range) due to non-normal distribution. All other values are displayed as mean ± 
SEM.
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Table 3
Gene expression, expressed as fold of expression in healthy controls, from bone cores and primary human 
osteoblasts from 24 dialysis patients undergoing bone biopsy. Data are expressed as medians (IQ ranges). A 
significant (p<0.05) difference in gene expression in CKD samples relative to healthy controls is denoted by 
an asterisk. Bold font denotes significant correlations between cores and cells.
Core Cells Correlation between
gene expression in
cores and cells
Osteoblast markers
OSX 8.84 (4.74, 13.84) * 2.93 (1.01, 5.20) * r=0.30, p=0.18
Runx2 3.36 (2.53, 5.49) * 2.61 (1.79, 3.40) * r=0.30, p=0.18
Col1A1 3.83 (3.28, 4.37) * 1.37 (1.10, 1.70) * r=0.34, p=0.12
BGLAP 7.91 (3.92, 10.44) * 1.13 (0.56, 2.03) r=0.19, p=0.39
OPG 4.23 (3.11, 7.08) * 1.38 (0.64, 1.92) * r=0.44, p=0.04
ALPL 5.15 (3.21, 6.41) * 2.96 (1.79, 5.59) * r=0.03, p=0.90
MGP 3.23 (1.69, 4.07) * 2.35 (1.24, 3.65) * r=0.18, p=0.43
BMP2 2.93 (1.81, 5.14) * 2.46 (1.74, 4.22) * r= − 0.06, p=0.80
Cell signaling
Cyp24A1 0.04 (0.01, 0.43) * 1.28 (0.45, 3.69) r=0.42, p=0.05
Cyp27B1 2.45 (1.66, 4.13) * 0.96 (0.77, 1.75) r=0.73, p=0.0001
VDR 2.49 (2.07, 3.88) * 2.79 (1.98, 3.97) * r=0.45, p=0.04
FGFR1 4.33 (2.52, 6.05) * 1.68 (1.13, 2.09) * r=0.49, p=0.02
PHEX 6.46 (4.42, 12.48) * 0.99 (0.70, 1.60) r=0.36, p=0.10
RANKL 6.50 (4.46, 12.08) * 1.63 (0.24, 2.98) * r= − 0.07, p=0.75
NHERF1 1.04 (0.82, 1.65) 2.42 (1.83, 3.19) * r=0.64, p=0.001
PTHR1 8.25 (4.91, 11.08) * 4.77 (1.83, 6.73) * r= − 0.18, p=0.43
IGF1 1.60 (1.19, 2.51) * 4.14 (1.96, 9.15) * r=0.47, p=0.03
Osteocyte markers
DMP 1 10.06 (5.21, 16.32) * 0.96 (0.53, 1.04) r=0.17, p=0.46
FGF23 3.88 (1.55, 8.95) * 1.10 (0.89, 1.22) r= − 0.06, p=0.80
MEPE 6.29 (4.38, 11.62) * 3.82 (2.22, 9.86) * r=0.04, p=0.85
SOST 4.15 (2.77, 9.02) * Not detected NA
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Table 4
Osteoblast, osteocyte, and cell-signaling genes assessed in cells and cores.
Protein name Number Gene name
Osteoblast markers
Osterix Hs01866874_s1 OSX
Cbfa1/Runx2 Hs00231692_m1 RUNX2
Collagen Type 1 Hs00164004_m1 Col1A1
Bone γ-Carboxyglutamate (gla) Protein Hs01587814_g1 BGLAP
Alkaline phosphatase Hs00758162_m1 ALPL
Matrix gla protein Hs00179899_m1 MGP
Bone morphogenic protein 2 Hs00154192_m1 BMP2
Cell signaling markers
Cyp24 H200167999_m1 Cyp24A1
Cyp27 Hs00168017_m1 Cyp27B1
Vitamin D receptor Hs01045840_m1 VDR
FGF receptor 1 Hs00241111_m1 FGFR1
Receptor activator of nuclear factor kappa-B ligand Hs00243522_m1 RANKL
Na(+)/H(+)-exchanger regulatory factor1 Hs00188594_m1 NHERF1
Parathyroid hormone receptor 1 Hs00174895_m1 PTHR1
Osteoprotegerin Hs00900358_m1 OPG
Insulin growth factor 1 Hs01547656_m1 IGF1
Osteocyte markers
Dentin matrix protein 1 Hs00189368_m1 DMP1
Fibroblast growth factor 23 Hs00221003_m1 FGF23
Matrix extracellular phosphoglycoprotein Hs00220237_m1 MEPE
PHEX Hs01011692_m1 PHEX
Sclerostin Hs00228830_m1 SOST
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